Tvardi Therapeutics

Tvardi Therapeutics

  • Founded: 2017
  • Location: Sugar Land, TX
  • Employee range: 1 - 10
  • Clinical stage: Clin2
  • Therapy area: Hepatocellular carcinoma (FT)
  • Drug types: ONC
  • Lead product: TTI-101
  • Product link:
  • Funding: $74M B Jun 2021; $9M A Sep 2018

job board

Short description:

STAT3 inhibitors

Drug notes:

Also Clin1b/Clin2 breast cancer, Clin1 solid tumors, Clin0 fibrosis; TTI-102 Clin0 undisclosed

Long description:

Contact us to add description:


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy